Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer

BACKGROUND: The aggressive clinical behavior of poorly differentiated and anaplastic thyroid cancers (PDTC and ATC) has proven challenging to treat, and survival beyond a few months from diagnosis is rare. Although 30%–60% of these tumors contain mutations in the BRAF gene, inhibitors designed speci...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Immunother Cancer
Auteurs principaux: Crespo-Rodriguez, Eva, Bergerhoff, Katharina, Bozhanova, Galabina, Foo, Shane, Patin, Emmanuel C, Whittock, Harriet, Buus, Richard, Haider, Syed, Muirhead, Gareth, Thway, Khin, Newbold, Kate, Coffin, Robert S, Vile, Richard G, Kim, Dae, McLaughlin, Martin, Melcher, Alan A, Harrington, Kevin J, Pedersen, Malin
Format: Artigo
Langue:Inglês
Publié: BMJ Publishing Group 2020
Sujets:
Oncolytic and Local Immunotherapy
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7445339/
https://ncbi.nlm.nih.gov/pubmed/32759235
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000698
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires